Regenerative Medicine Initiatives


In the regenerative medicine field, we have formed an investment and business alliance with Promethera Biosciences SA (Promethera SA), a regenerative medicine startup developing liver-derived cell-based medicines.

Promethera SA develops cell-based products for regenerative medicine (allogeneic/cell-based medicine) derived from the liver tissue of healthy donors. These products are undergoing clinical trials to evaluate their safety and initial efficacy as therapeutic agents to treat such diseases as urea cycle disorder (UCD), acute-on-chronic liver failure (ACLF), and non-alcoholic steatohepatitis (NASH). Promethera SA is steadily progressing with its plan to make its world-first liver disease medicines a reality.

Also in the field of regenerative medicine, we have invested in Organ Technologies, Inc., a startup with initiatives in therapeutic development using cell culture technology, including alopecia treatment and implants.

ITOCHU aims to provide solutions using new technologies to relieve ailments inadequately treated by conventional synthetic drugs. We will do this by leveraging know-how accumulated in our pharmaceutical-related businesses while engaging with partners that boast superior technologies.